Sanofi Analyst Recommends Caution As Stock Continues Golden Run After Q3-Print

ICICI Direct analysts noted that Sanofi’s Q4CY22 numbers were weak in-line with their expectations.

The Sanofi Analyst: The Siddhant Khandekar-led analyst team at ICICI Direct maintained its ‘hold’ rating for the stock with a target price of ₹6,270.

The Sanofi Thesis: ICICI Direct noted that the company’s numbers dropped sequentially in line with its expectation as its growth momentum is yet to reach pre-Covid level.

See Also: Why Are Cipla Shares Tanking Today

The analysts highlighted that the company’s revenue from operations fell around 2.9% sequentially to ₹672 crore. The company’s EBITDA margin also contracted 145 bps quarter-over-quarter to 24.8%. The firm also noted that the company “has underperformed the Indian Pharmaceutical Market due to below-par performances of some tail brands.”

However, analysts noted that the company has a strong balance sheet and a good dividend payout track record. The firm said that it waits for visible growth triggers in power brands portfolio especially in the anti-diabetic and cardiovascular therapies as it maintained its hold rating for the stock.

News that Moves

Get Ring The Bell, Benzinga India’s weekly briefing. Designed specifically for investors like you.

Price Action: Sanofi shares were up 0.93% at ₹5,916.75 as the markets opened for business on Tuesday.

Read Next: Why Apollo Hospital Analysts See Double Figure Upside Even After Q3 Earnings Miss

Posted In: healthcareICICI DirectpharmaPharmaceuticalQ3FY23Sanofi